Food intake: Whom controls what?;Prise alimentaire: Qui contrôle quoi?

Annales d'Endocrinologie

Volumn 63, Issue 6 II, 2002, Pages

  Dadoun, F ^a  

^a NONE

Author keywords

Food intake; Hypothalamus; Leptin; Neuromediators; Neuropeptides; Obesity

Indexed keywords

LEPTIN; NEUROPEPTIDE;

ANIMAL MODEL; AUTONOMIC NERVOUS SYSTEM; BODY WEIGHT; CONFERENCE PAPER; FOOD INTAKE; HOMEOSTASIS; HYPOPHYSIS FUNCTION; HYPOTHALAMUS; METABOLISM; NONHUMAN; NUTRITIONAL STATUS; OBESITY; REGULATORY MECHANISM;

EID: 0036953029     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev 1987; 8: 256-287.
2. Flier JS, Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998; 92: 437-440.
3. Kalra SP, Dube MG, Pu S et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
4. Schwartz MW, Woods SC, Porte D Jr et al. Central nervous system control of food intake. Nature 2000; 404: 661-671.
5. Jéquier E, Tappy L. Regulation of body weight in humans. Physiol Rev 1999; 79: 451-480.
6. Woods SC, Seeley RJ. Adiposity signals and the control of energy homeostasis. Nutrition 2000; 16: 894-902.
7. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104: 531-543.
8. Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med 2001; 226: 963-977.
9. Blundell JE, Lawton CL, Cotton JR et al. Control of human appetite: implications for the intake of dietary fat. Annu Rev Nutr 1996; 16: 285-319.
10. Smith GP, Gibbs J. Satiating effect of cholecystokinin. Ann N Y Acad Sci 1994; 713: 236-241.
11. Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal homone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10: 229-235.
12. Rose C, Vargas F, Facchinetti P et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 1996; 380: 403-409.
13. Flier JS, Maratos-Flier E. The stomach speaks-ghrelin and weight regulation. N Engl J Med 2002; 346: 1662-1663.
14. Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
15. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
16. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
17. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
18. Caixas A, Bashore C, Nash W et al. Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 2002; 87: 1902.
19. Tschop M, Weyer C, Tataranni PA et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709.
20. Otto B, Cuntz U, Fruehauf E et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-673.
21. Toshinai K, Mondal MS, Nakazato M et al. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001; 281: 1220-1225.
22. Shintani M, Ogawa Y, Ebihara K et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-232.
23. English PJ, Ghatei MA, Malik IA et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984.
24. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
25. Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond 1953; 140: 579-592.
26. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141-148.
27. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
28. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271.
29. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
30. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413- 437.
31. Ahima RS, Saper CB, Flier JS et al. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000; 21: 263- 307.
32. Porte D Jr, Seeley RJ, Woods SC et al. Obesity, diabetes and the central nervous system. Diabetologia 1998; 41: 863-881.
33. Considine RV, Considine EL, Williams CJ et al. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995; 95: 2986-2988.
34. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
35. Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nature Med 1995; 1: 1155-1161.
36. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
37. Clement K, Vaisse C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.
38. Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161.
39. Zakrzewska KE, Cusin I, Sainsbury A et al. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997; 46: 717-719.
40. Bjorbaek C, Elmquist JK, Frantz JD et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Molecular Cell 1998; 1998: 619-625.
41. Ahima RS, Prabakaran D, Mantzoros C et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-252.
42. Coleman RA, Herrmann TS. Nutritional regulation of leptin in humans. Diabetologia 1999; 42: 639-646.
43. Gura T. Obesity research. Leptin not impressive in clinical trial. Science 1999; 286: 881-882.
44. Lee DW, Leinung MC, Rozhavskaya-Arena M et al. Leptin and the treatment of obesity: its current status. Eur J Pharmacol 2002; 440: 129-139.
45. Rohner-Jeanrenaud F. A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Int J Obes Relat Metab Disord 1995; 19: 517-534.
46. Leibowitz SF. Brain peptides and obesity: pharmacologic treatment. Obes Res 1995; 3[suppl]: 573S-589S.
47. Leibel RL, Chung WK, Chua SC Jr. The molecular genetics of rodent single gene obesities. J Biol Chem 1997; 272: 31937-31940.
48. Schalling M, Johansen J, Nordfors L et al. Genes involved in animal models of obesity and anorexia. J Intern Med 1999; 245: 613-619.
49. Elmquist JK. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol Behav 2001; 74: 703-708.
50. Williams G, Bing C, Cai XJ et al. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683-701.
51. Kalra SP, Kalra PS. Is neuropeptide Y a naturally occurring appetite transducer? Curr Opin Endocrinol Diab 1996; 3: 157-163.
52. Bischoff A, Michel MC. Emerging functions for neuropeptide Y5 receptors. Trends Pharmacol Sci 1999; 20: 104-106.
53. Cone RD. The Central Melanocortin System and Energy Homeostasis. Trends Endocrinol Metab 1999; 10: 211-216.
54. Wilson BD, Ollmann MM, Barsh GS. The role of agouti-related protein in regulating body weight. Mol Med Today 1999; 5: 250-256.
55. Vaisse C, Clement K, Durand E et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106: 253-262.
56. Lee YS, Poh LK, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 2002; 87: 1423-1426.
57. Krude H, Biebermann H, Luck W et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155-157.
58. Kuhar MJ, Dall Vechia SE. CART peptides: novel addiction- and feeding-related neuropeptides. Trends Neurosci 1999; 22: 316-320.
59. Shimada M, Tritos NA, Lowell BB et al. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396: 670-674.
60. Marsh DJ, Weingarth DT, Novi DE et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002; 99: 3240-3245.
61. Ludwig DS, Tritos NA, Mastaitis JW et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Cin Invest 2001; 107: 379-386.
62. Willie JT, Chemelli RM, Sinton CM et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24: 429-458.